JO
ENGN icon

John Overdeck’s enGene Therapeutics ENGN Stock Holding History

John Overdeck’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
164,570
+5,501
+3% +$22.4K ﹤0.01% 4564
2026
Q1 		$1.08M Sell
159,069
-2,443
-2% -$21.7K ﹤0.01% 3208
2025
Q4 		$1.46M Buy
+161,512
New +$1.29M ﹤0.01% 2682
2025
Q2 		– Sell
-15,832
Closed -$70.9K – 3261
2025
Q1 		$70.9K Sell
15,832
-20,034
-56% -$124K ﹤0.01% 3003
2024
Q4 		$239K Sell
35,866
-3,755
-9% -$29.2K ﹤0.01% 2816
2024
Q3 		$261K Buy
+39,621
New +$295K ﹤0.01% 2729

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

John Overdeck's ENGN Position: Q2 2026 in Review

John Overdeck increased its enGene Therapeutics (ENGN) stake by 3.5% in Q2 2026, buying an estimated $22.4K and bringing the position to 164,570 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #4564.

John Overdeck first reported a position in ENGN in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.46M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • John Overdeck held 164,570 shares of enGene Therapeutics worth $285K as of Q2 2026.
  • John Overdeck bought 5,501 enGene Therapeutics shares in Q2 2026, an estimated $22.4K.
  • enGene Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4564 holding.
  • John Overdeck first reported a position in enGene Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • John Overdeck's enGene Therapeutics position peaked at $1.46M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.